METUPUK are saddened by the news that one of our members and friend Asha Umrawsingh has died. Asha’s diagnosis and access to treatment was a roller coaster of how strict
Asha Umrawsingh
METUPUK at the UK Interdisciplinary Breast Cancer Symposium
METUPUK (Metastatic Exchange To Unleash Power) attended the 2024 United Kingdom’s Interdisciplinary Breast Cancer Symposium in Birmingham, hosted by Breast Cancer Now and supported by numerous partners. It was a
PARP inhibitor Talazoparib recommended by NICE for the treatment of hereditary BRCA mutated metastatic breast cancer
METUPUK are delighted by the National Institute of Clinical Excellence (NICE) decision to recommend Talazoparib (Talzenna ®, Pfizer Ltd.) for treating HER2-negative, locally advanced or metastatic breast cancer with germline
NICE Methodology Roundtable Discussion
In November 2023 METUPUK trustee Madeleine Meynell was a panel member at the event Optimising NICE outcomes: Policy roundtable on the evolution of NICE methodology and how patient organisations can
NICE invites comments from the public on the draft guidance to not recommend the parp inhibitor talazoparib
METUPUK are disappointed by the National Institute of Clinical Excellence (NICE) decision to not recommend talazoparib (Talzenna ®, Pfizer Ltd.) for treating HER2-negative, locally advanced or metastatic breast cancer with
Kit Dzeryn
Sadly our Kit @Diamondtrees11 died on Monday 7th May. Her husband Phillip contacted us with the tragic news. We didn’t meet Kit but she was an integral part of METUPUK
On the trail of a clinical trial (Kit’s story)
Clinical trials are essential for testing new treatments for metastatic breast cancer. For patients, they represent hope – the chance to get access to a new potential treatment before it
Abemaciclib – new treatment
Starting a new medication can be a daunting experience, especially if the medication is still fairly new to the market. Abemaciclib may not be a household name, but for those
Drug access – drug hope vs financial approval…
I contacted METUPUK when I was diagnosed as a primary patient in 2018. Even though my mum died of secondary breast cancer in 2015 I had no real understanding of the metastatic disease and the challenges patients face getting access to the treatment they need.
Dr Rachel Eyre interviews Dr Hannah Harrison about breast cancer research
Scientific research is vital for the development of new and improved treatments for secondary breast cancer. But what’s it like to be a scientist working in this area? Dr Hannah Harrison received her PhD in breast cancer research from the University of Manchester in 2009 and has since worked as a breast cancer research scientist in the Manchester Cancer Research Centre. Here, Hannah tells us about her work.